Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.74 |
| ▸ | MAPT | P10636 | 5/20 | 0.65 |
| ▸ | NPC1 | O15118 | 4/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | MYOC | Q99972 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.57 |
| ▸ | PTGES | O14684 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11047722 | 1.00 | MEN1 (0.74) | MEN1KMT2AMAPTNPC1MAPK1 | |
| SCHEMBL8956783 | 0.93 | MEN1 (0.64) | MEN1KMT2AMAPTNPC1MAPK1 | |
| SCHEMBL4110398 | 0.88 | ABCG2 (0.73) | MEN1KMT2AMAPTNPC1MAPK1 | |
| SCHEMBL15306499 | 0.87 | CNR1 (0.77) | MEN1KMT2AMAPTMAPK1LMNA | |
| SCHEMBL11972987 | 0.86 | LMNA (0.70) | MEN1KMT2AMAPTNPC1MAPK1 | |
| SCHEMBL1177730 | 0.86 | MEN1 (1.00) | MEN1KMT2AMAPTNPC1MAPK1 | |
| SCHEMBL6302157 | 0.86 | MEN1 (1.00) | MEN1KMT2AMAPTNPC1MAPK1 | |
| SCHEMBL11069641 | 0.86 | ALDH1A1 (0.67) | MEN1KMT2AMAPTNPC1MAPK1 | |
| SCHEMBL4122859 | 0.86 | MEN1 (0.73) | MEN1KMT2AMAPTNPC1MAPK1 | |
| SCHEMBL4118564 | 0.86 | GAA (0.73) | MEN1KMT2AMAPTNPC1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | MEN1 3273/4885KMT2A 2807/4885MAPT 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.